China Pharma Holdings (CPHI) Research & Development (2013 - 2026)

China Pharma Holdings (CPHI) has reported Research & Development for 14 consecutive years, with $19135.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 8.67% year-over-year to $19135.0; the trailing twelve-month figure through Jun 2026 stood at $333259.0 (up 140.28% YoY), and the FY2025 full-year result was $280901.0, down 1.07% from the prior year.
• Research & Development retreated to $19135.0 in Q2 2026 per CPHI's latest filing, from $83762.0 in the prior quarter.
• Across five years, Research & Development topped out at $190041.0 in Q4 2025 and bottomed at $547.0 in Q4 2024.
• Historically, Research & Development has averaged $60759.9 across 5 years, with a median of $35886.0 in 2024.
• The sharpest annual moves came in 2024 and 2025: Research & Development sank 99.63% in 2024, then jumped 34642.41% in 2025.
• Over 5 years, Research & Development stood at $27999.0 in 2022, then surged by 426.99% to $147552.0 in 2023, then tumbled by 99.63% to $547.0 in 2024, then surged by 34642.41% to $190041.0 in 2025, then tumbled by 89.93% to $19135.0 in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $19135.0, $83762.0, and $190041.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.